Shengjiang Xiexin decoction combined with vancomycin for Clostridioides difficile infection: impact of vancomycin dose-reduction strategy on gut microbiota homeostasis and recurrence risk
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2025.1740179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Lin Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Vancomycin, Drugs, Chinese Herbal, Anti-Bacterial Agents, Gastrointestinal Microbiome. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Even though relapse rates for Clostridioides difficile infection (CDI) are high, vancomycin—a medication that targets C. difficile and works well during acute episodes—has gut microbiota-disrupting effects. The Chinese herbal formula Shengjiang Xiexin decoction (SXD) is helpful for microbial reversion, justifying the use of combination therapy. One often invoked tactic in such bundles of care is to minimize patients’ antibiotic exposure. In this work, we challenged this paradigm in a murine CDI model. Divergently with regard to the dose deescalation (low-dose vs. short-course), we found that it significantly undermined the synergy between the drugs. Despite the resolution of acute symptoms by all combination regimens containing SXD, deescalation strategies (CDR2 and CDR3) resulted in significantly worse relapse, enhanced inflammation and sustained gut dysbiosis. Conversely, only the CDR1 regimen with SXD co-treatment resulted in a full recovery of gut microbiota alpha-diversity and long-term ecological stability, associated with a better shift of metabolic pathways. Accordingly, our key finding is that standard vancomycin dosing is necessary for this therapeutic synergy to be realized and that dose deescalation blunts it and raises the risk of relapse. Such evidence invites a more sophisticated antibiotic stewardship approach with concomitant treatments, favoring preservation of synergistic effect over simplistic dose reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
- Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Zhu, L., Chen, L. S., Ma, F. Z., Peng, J. E., Wang, Y. B., Ma, Y. Q., Xu, Y., Wang, Y., Yeerjiang, A., Zhang, C. E., & Ma, Z. J. (2026). Shengjiang Xiexin decoction combined with vancomycin for Clostridioides difficile infection: impact of vancomycin dose-reduction strategy on gut microbiota homeostasis and recurrence risk. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1740179
Vancouver
Zhu L, Chen LS, Ma FZ, Peng JE, Wang YB, Ma YQ, et al. Shengjiang Xiexin decoction combined with vancomycin for Clostridioides difficile infection: impact of vancomycin dose-reduction strategy on gut microbiota homeostasis and recurrence risk. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2025.1740179
BibTeX
@article{Zhu2026,
author = {Zhu, Lin and Chen, Li-Sheng and Ma, Fu-Zhi and Peng, Jin-E and Wang, Yu-Bu and Ma, Yu-Qing and Xu, Yue and Wang, Yi and Yeerjiang, Ayiman and Zhang, Cong-En and Ma, Zhi-Jie},
title = {Shengjiang Xiexin decoction combined with vancomycin for Clostridioides difficile infection: impact of vancomycin dose-reduction strategy on gut microbiota homeostasis and recurrence risk},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2025.1740179}
}
EUVIMED